{"title":"现在是加快建设当地疫苗佐剂生产能力的时候了。","authors":"Christopher B Fox","doi":"10.1177/2051013617733259","DOIUrl":null,"url":null,"abstract":"Recent accomplishments in vaccine adjuvant development are enabling new vaccines for previously intractable diseases, increased immunity in immunocompromised populations and greater global pandemic preparedness.1,2 To ensure that the potential benefits of vaccine adjuvant technology are widely accessible, it is essential that adjuvant molecules and formulations, as well as the know-how to manufacture and clinically evaluate them, are made available to developing country manufacturers.","PeriodicalId":33285,"journal":{"name":"Therapeutic Advances in Vaccines and Immunotherapy","volume":"5 6","pages":"111-113"},"PeriodicalIF":0.0000,"publicationDate":"2017-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1177/2051013617733259","citationCount":"5","resultStr":"{\"title\":\"It is time to accelerate building local vaccine adjuvant manufacturing capacity.\",\"authors\":\"Christopher B Fox\",\"doi\":\"10.1177/2051013617733259\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Recent accomplishments in vaccine adjuvant development are enabling new vaccines for previously intractable diseases, increased immunity in immunocompromised populations and greater global pandemic preparedness.1,2 To ensure that the potential benefits of vaccine adjuvant technology are widely accessible, it is essential that adjuvant molecules and formulations, as well as the know-how to manufacture and clinically evaluate them, are made available to developing country manufacturers.\",\"PeriodicalId\":33285,\"journal\":{\"name\":\"Therapeutic Advances in Vaccines and Immunotherapy\",\"volume\":\"5 6\",\"pages\":\"111-113\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1177/2051013617733259\",\"citationCount\":\"5\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapeutic Advances in Vaccines and Immunotherapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/2051013617733259\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2017/10/9 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Vaccines and Immunotherapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/2051013617733259","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2017/10/9 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
It is time to accelerate building local vaccine adjuvant manufacturing capacity.
Recent accomplishments in vaccine adjuvant development are enabling new vaccines for previously intractable diseases, increased immunity in immunocompromised populations and greater global pandemic preparedness.1,2 To ensure that the potential benefits of vaccine adjuvant technology are widely accessible, it is essential that adjuvant molecules and formulations, as well as the know-how to manufacture and clinically evaluate them, are made available to developing country manufacturers.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
